Invasive breast cancer recurrence was significantly reduced with extended aromatase inhibitor therapy. 2. No significant ...

GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets. 2. Includes a PDE3/4 inhibitor for COPD plus programs in oncology, respiratory, ...

Schrödinger discontinued its SGR-2921 CDC7 inhibitor program following two treatment-related deaths in a Phase 1 trial. 2. AML patients showed early signs of benefit, but safety concerns led to an ...

Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. 2.

Medical cannabis has a high discontinuation rate among patients with chronic musculoskeletal pain, particularly in the first ...

First FDA-approved therapy for non-cystic fibrosis bronchiectasis; addresses a major unmet respiratory need. 2. Phase 3 data ...

Progression-free survival and overall survival were significantly greater in the combination therapy group compared to ...

Patients with severely disturbed sleep had the highest comorbidity burden, lowest ejection fraction, and poorest cognitive ...

Higher Post-operative Day 1 (POD1) pain scores were independently associated with increased 30-day infectious and ...